Effect of Iohexol and Diatrizoate on Pulmonary Arterial Pressure following Pulmonary Angiography

1988 ◽  
Vol 29 (4) ◽  
pp. 487-490 ◽  
Author(s):  
H. Tajima ◽  
T. Kumazaki ◽  
N. Tajima ◽  
K. Ebata
Keyword(s):  
Arterial Pressure ◽  
Contrast Medium ◽  
Pulmonary Arterial Pressure ◽  
Random Order ◽  
Normal Pressure ◽  
Pulmonary Angiography ◽  
Double Blind ◽  
Pulmonary Arterial ◽  
Double Blind Crossover Study ◽  
Made In

A clinical comparison of the effects on pulmonary arterial pressure produced by iohexol and diatrizoate, following selective pulmonary angiography, was made in 17 patients with a normal pressure before the injection of the contrast medium. A double blind crossover study was performed and each contrast medium was administered in random order. The pulmonary arterial pressure was continuously recorded before, during and after the injection for 3 minutes. The effect of iohexol on the pulmonary arterial pressure was significantly less than that of diatrizoate. The results indicated that iohexol should be better tolerated than diatrizoate and therefore a safer contrast medium for selective pulmonary angiography.

scholarly journals Effect of an Iso-Osmolar Contrast Medium on Pulmonary Arterial Pressure at Pulmonary Angiography

1991 ◽  
Vol 32 (2) ◽  
pp. 134-136 ◽  
Author(s):  
Hiroyuki Tajima ◽  
T. Kumazaki ◽  
K. Ito ◽  
N. Tajima ◽  
K. Gemma ◽  
...  
Keyword(s):  
Arterial Pressure ◽  
Contrast Medium ◽  
Pulmonary Arterial Pressure ◽  
Pulmonary Angiography ◽  
Pulmonary Arterial

Effect of an Iso-Osmolar Contrast Medium on Pulmonary Arterial Pressure at Pulmonary Angiography

1991 ◽  
Vol 32 (2) ◽  
pp. 134-136 ◽  
Author(s):  
H. Tajima ◽  
T. Kumazaki ◽  
K. Ito ◽  
N. Tajima ◽  
K. Gemma ◽  
...  
Keyword(s):  
Arterial Pressure ◽  
Contrast Medium ◽  
Pulmonary Arterial Pressure ◽  
Pulmonary Angiography ◽  
Pulmonary Arterial

Pulmonary gas exchange in humans exercising at sea level and simulated altitude

1986 ◽  
Vol 61 (1) ◽  
pp. 260-270 ◽  
Author(s):  
P. D. Wagner ◽  
G. E. Gale ◽  
R. E. Moon ◽  
J. R. Torre-Bueno ◽  
B. W. Stolp ◽  
...  
Keyword(s):  
Gas Exchange ◽  
Arterial Pressure ◽  
Sea Level ◽  
Pulmonary Arterial Pressure ◽  
Minute Ventilation ◽  
Statistical Significance ◽  
Random Order ◽  
Normal Subjects ◽  
Simulated Altitude ◽  
Pulmonary Arterial

In a previous study of normal subjects exercising at sea level and simulated altitude, ventilation-perfusion (VA/Q) inequality and alveolar-end-capillary O2 diffusion limitation (DIFF) were found to increase on exercise at altitude, but at sea level the changes did not reach statistical significance. This paper reports additional measurements of VA/Q inequality and DIFF (at sea level and altitude) and also of pulmonary arterial pressure. This was to examine the hypothesis that VA/Q inequality is related to increased pulmonary arterial pressure. In a hypobaric chamber, eight normal subjects were exposed to barometric pressures of 752, 523, and 429 Torr (sea level, 10,000 ft, and 15,000 ft) in random order. At each altitude, inert and respiratory gas exchange and hemodynamic variables were studied at rest and during several levels of steady-state bicycle exercise. Multiple inert gas data from the previous and current studies were combined (after demonstrating no statistical difference between them) and showed increasing VA/Q inequality with sea level exercise (P = 0.02). Breathing 100% O2 did not reverse this increase. When O2 consumption exceeded about 2.7 1/min, evidence for DIFF at sea level was present (P = 0.01). VA/Q inequality and DIFF increased with exercise at altitude as found previously and was reversed by 100% O2 breathing. Indexes of VA/Q dispersion correlated well with mean pulmonary arterial pressure and also with minute ventilation. This study confirms the development of both VA/Q mismatch and DIFF in normal subjects during heavy exercise at sea level. However, the mechanism of increased VA/Q mismatch on exercise remains unclear due to the correlation with both ventilatory and circulatory variables and will require further study.

scholarly journals Sildenafil for pulmonary hypertension due to left-toright shunt after corrective procedure

2015 ◽  
Vol 55 (5) ◽  
pp. 257
Author(s):  
Dyahris Kuntartiwi ◽  
Piprim Basarah Yanuarso ◽  
Sudigdo Sastroasmoro
Keyword(s):  
Pulmonary Hypertension ◽  
Arterial Pressure ◽  
Clinical Outcomes ◽  
Congenital Heart ◽  
Pulmonary Arterial Pressure ◽  
Common Complication ◽  
Double Blind ◽  
Pulmonary Arterial ◽  
To Receive ◽  
Corrective Procedures

Background Pulmonary arterial hypertension (PAH) is a common complication seen in those with a left-to-right shunt congenital heart defect (CHD). Corrective procedures by surgery or catheterization are the therapies of choice for reversible PAH. Since morbidity and mortality due to PAH after correction is high, sildenafil has been used as a selective vasodilator of the pulmonary artery, in order to decrease pulmonary arterial pressure. Objectives To evaluate the effect of sildenafil on pulmonary arterial pressure and clinical outcomes after left-to-right shunt CHD corrective procedures. Methods Left-to-right shunt patients aged < 18 years scheduled for corrective treatment were randomized in a double-blind fashion, to receive either oral sildenafil or placebo, given on days 3 to 30 after the corrective procedure. Clinical and pulmonary arterial pressures were evaluated by echocardiography before, 3 days after, and 30 days after the corrective procedure. Results From July 2013 to June 2014, 36 patients were included in the study: 17 in the placebo and 19 in the sildenafil groups. There were no differences in pulmonary arterial pressure or in clinical outcomes after corrective procedure between the two groups. There were no adverse events during the treatment. Conclusion Sildenafil has little effect on decreasing pulmonary arterial pressure, as most of our subjects seem to have hyperkinetic PAH. As such, pulmonary arterial pressure returns to normal soon after corrective procedures.

scholarly journals Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Zixuan Pan ◽  
Alberto M. Marra ◽  
Nicola Benjamin ◽  
Christina A. Eichstaedt ◽  
Norbert Blank ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Arterial Pressure ◽  
Primary Endpoint ◽  
Pulmonary Arterial Pressure ◽  
Controlled Study ◽  
Heart Catheterization ◽  
Double Blind ◽  
Mean Pulmonary Arterial Pressure ◽  
Parallel Group ◽  
Pulmonary Arterial

Abstract Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH). Methods Thirty-eight SSc patients with mildly elevated mPAP at rest between 21 and 24 mmHg and/or > 30 mmHg during low-dose exercise were randomly assigned to treatment with either ambrisentan 5–10 mg/day or placebo. Right heart catheterization and further clinical parameters were assessed at baseline and after 6 months. The primary endpoint was the difference of mPAP change at rest between groups. Results After 6 months, the two groups did not differ in the primary endpoint (ambrisentan mPAP − 1 ± 6.4 mmHg vs. placebo − 0.73 ± 3.59 mmHg at rest, p = 0.884). However, three patients from the placebo group but none of the ambrisentan group progressed to SSc-associated pulmonary arterial hypertension. Furthermore, ambrisentan treatment showed significant improvements in the secondary endpoints cardiac index (CI) and pulmonary vascular resistance (PVR) at rest (CI 0.36 ± 0.66 l/min/m2 vs. − 0.31 ± 0.71 l/min/m2, p = 0.010; PVR − 0.70 ± 0.78 WU vs. 0.01 ± 0.71 WU, p = 0.012) and during exercise (CI 0.7 ± 0.81 l/min/m2 vs. − 0.45 ± 1.36 l/min/m2, p = 0.015; PVR − 0.84 ± 0.48 WU vs. − 0.0032 ± 0.34 WU, p < 0.0001). Conclusion This is the first randomized, double-blind, placebo-controlled study testing the effect of ambrisentan in patients with mildly elevated mPAP and/or exercise PH. The primary endpoint change in mPAP did only tendentially improve in the ambrisentan group, but the significant improvement of other hemodynamic parameters points to a possible benefit of ambrisentan and will be helpful to design future trials. Trial registration www.ClinicalTrials.gov, unique identifier NCT: NCT02290613, registered 14th of November 2014.

Sign in / Sign up

Export Citation Format

Share Document